Children With Cystic Fibrosis Have Elevated Levels of Fecal Chitinase-3-like-1.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
28
5
2022
medline:
30
6
2022
entrez:
27
5
2022
Statut:
ppublish
Résumé
Although chitinase-3-like-1 (CHI3L1), predominately produced by epithelial cells and macrophages, is relevant to pulmonary disease in cystic fibrosis (CF), fecal levels have not yet been assessed in children with CF. Fecal CHI3L1 was measured with a commercial immunoassay using fecal samples provided by children with CF and healthy control (HC) children. Higher median (interquartile range) fecal CHI3L1 levels were seen in the 52 children with CF than in the 35 controls: 15.97 (3.34-50.53) ng/g versus 2.93 (2.13-9.27) ng/g ( P = 0.001). Fecal CHI3LI did not differ according to sex. In the children with CF, fecal CHI3L1 levels did not correlate with growth parameters nor were the levels affected by pancreatic insufficiency. Children with CF had higher fecal CHI3L1 levels, suggesting underlying gut inflammation. Further work is required to confirm the current findings and to ascertain the longer-term significance of elevated CHI3L1.
Identifiants
pubmed: 35622011
doi: 10.1097/MPG.0000000000003477
pii: 00005176-202207000-00009
doi:
Substances chimiques
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Chitinases
EC 3.2.1.14
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-51Informations de copyright
Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
C.Y.O. has consulted and served on advisory boards for Vertex Pharmaceuticals (unrelated to this manuscript). A.S.D. has served on advisory boards for Janssen, Abbvie, and Nestle (all unrelated to this manuscript). The remaining authors report no conflicts of interest.
Références
Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–51.
Werlin SL, Benuri-Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010;51:304–8.
Garg M, Leach ST, Coffey MJ, et al. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros. 2017;16:631–6.
Dhaliwal J, Leach S, Katz T, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60:521–6.
Coffey MJ, Nielsen S, Wemheuer B, et al. Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis. Sci Rep. 2019;9:18593.
Mizoguchi E. Chitinase 3–like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology. 2006;130:398–411.
Volkers A, Appleton L, Leach ST, et al. Chitinase 3-Like-1 Protein: a novel biomarker of disease activity and risk of relapse in children with inflammatory bowel disease. Gastroenterology. 2019;156:S391.
Aomatsu T, Imaeda H, Matsumoto K, et al. Faecal chitinase 3-like1: a novel biomarker of disease activity in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:941–8.
Hector A, Kormann MSD, Mack I, et al. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease. PLoS One. 2011;6:e24399.
Leonardi S, Parisi GF, Capizzi A, et al. YKL-40 as marker of severe lung disease in cystic fibrosis patients. J Cyst Fibros. 2016;15:583–6.
Fantino E, Gangell CL, Hartl D, et al. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med. 2014;14:28.
Buisson A, Vazeille E, Minet-Quinard R, et al. Faecal chitinase 3-like-1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069–79.
Garg M, Leach ST, Pang T, et al. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10 years old. J Cyst Fibros. 2018;17:109–13.
Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332:494–9.
Abraham JM, Taylor CJ. Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16:S40–9.
Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and Chitinase/Chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501.
Zhao T, Su Z, Li Y, et al. Chitinase-3 like-protein-1 function and its role in diseases. Sig Transduct Target Ther. 2020;5:201.
Kamba A, Lee I-A, Mizoguchi E. Potential association between TLR4 and chitinase 3-like-1 (CH3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer. Curr Mol Med. 2013;13:1110–21.
Kawada M, Seno H, Kanda K, et al. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012;31:3111–23.
Lévêque M, Le Trionnaire S, Del Porto P, et al. The impact of impaired macrophage functions in cystic fibrosis disease progression. J Cyst Fibros. 2017;16:443–53.
Bonfield TL. Macrophage dysfunction in cystic fibrosis: a therapeutic target to enhance self-immunity. Am J Respir Crit Care Med. 2015;192:1406–7.